Global Nephro Genetic Testing Market
Global Nephro Genetic Testing Market

Nephro Genetic Testing Comprehensive Study by Test (Blood Tests, Urine Tests), End-Use Industries (Hospitals, Clinic Centre, Pharmaceuticals, Research institutes, Diagnostics laboratories), Diagnosis (CT Scans, MRIs, Ultrasounds, Kidney Function Test, Urinalysis) Players and Region - Global Market Outlook to 2026

Nephro Genetic Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 245 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Nephro Genetic Testing Market Overview:
A nephrologist is a type of diagnosis and treatment of kidney conditions. It allows performing a very long list of tests, procedures, and treatments.

Growth Drivers
  • An increasing number of kidney diseases that drive the growth of the market
  • Increased utilization of diagnostic genetic testing in nephrology

Roadblocks
  • Factors such as medical risk, high blood pressure, heart conditions, pain, fluid in the joints, or stiffness that hampering the growth of the market

Opportunities
  • Technological advancement in genetic diagnostic has various genes involved in kidney pathophysiology

Challenges
  • The challenging task of selecting the most suitable genetic test for each patient


Competitive Landscape:
Companies in the market are concentrating on nephron genetic testing. In North America, governmental initiatives for genetic testing and increase in funding act as a driver for the market.
Some of the key players profiled in the report are Centogene (Germany), MeGenome (India), Blueprint Genetics Oy (Finland), Invitae Corporation (United States) and Natera Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Nephro Genetic Testing market by 2026. Considering Market by Test , the sub-segment i.e. Blood Tests will boost the Nephro Genetic Testing market. Considering Market by End-Use Industries , the sub-segment i.e. Hospitals will boost the Nephro Genetic Testing market. Considering Market by Diagnosis, the sub-segment i.e. CT Scans will boost the Nephro Genetic Testing market.

Jun 1, 2021: Centogene launched NEW CentoXome, an exome sequencing solution. This solution provides best-in-class clinical insights based on CENTOGENE’s unique rare disease-centric Bio/Databank, and it enables more rapid diagnosis and identification of treatment options.

What Can be Explored with the Nephro Genetic Testing Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Nephro Genetic Testing Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Nephro Genetic Testing
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Nephro Genetic Testing market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Nephro Genetic Testing market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Government Agency, Suppliers, Healthcare Industry and Clinic Centres.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Nephro Genetic Testing Market?
The Nephro Genetic Testing market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Nephro Genetic Testing Market?
Top performing companies in the Global Nephro Genetic Testing market are Centogene (Germany), MeGenome (India), Blueprint Genetics Oy (Finland), Invitae Corporation (United States) and Natera Inc. (United States), to name a few.

3. What trending factors would impact Nephro Genetic Testing Market growth most?
"Technological advancements in DNA sequencing techniques and increasing research & development" is seen as one of major influencing trends for Nephro Genetic Testing Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Test
  • Blood Tests
  • Urine Tests

By End-Use Industries
  • Hospitals
  • Clinic Centre
  • Pharmaceuticals
  • Research institutes
  • Diagnostics laboratories

By Diagnosis
  • CT Scans
  • MRIs
  • Ultrasounds
  • Kidney Function Test
  • Urinalysis

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. An increasing number of kidney diseases that drive the growth of the market
      • 3.2.2. Increased utilization of diagnostic genetic testing in nephrology
    • 3.3. Market Challenges
      • 3.3.1. The challenging task of selecting the most suitable genetic test for each patient
    • 3.4. Market Trends
      • 3.4.1. Technological advancements in DNA sequencing techniques and increasing research & development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nephro Genetic Testing, by Test , End-Use Industries , Diagnosis and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Nephro Genetic Testing (Value)
      • 5.2.1. Global Nephro Genetic Testing by: Diagnosis (Value)
        • 5.2.1.1. CT Scans
        • 5.2.1.2. MRIs
        • 5.2.1.3. Ultrasounds
        • 5.2.1.4. Kidney Function Test
        • 5.2.1.5. Urinalysis
      • 5.2.2. Global Nephro Genetic Testing Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Nephro Genetic Testing (Price)
  • 6. Nephro Genetic Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Centogene (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. MeGenome (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Blueprint Genetics Oy (Finland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Invitae Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Natera Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Nephro Genetic Testing Sale, by Test , End-Use Industries , Diagnosis and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Nephro Genetic Testing (Value)
      • 7.2.1. Global Nephro Genetic Testing by: Diagnosis (Value)
        • 7.2.1.1. CT Scans
        • 7.2.1.2. MRIs
        • 7.2.1.3. Ultrasounds
        • 7.2.1.4. Kidney Function Test
        • 7.2.1.5. Urinalysis
      • 7.2.2. Global Nephro Genetic Testing Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Nephro Genetic Testing (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nephro Genetic Testing: by Diagnosis(USD Million)
  • Table 2. Nephro Genetic Testing CT Scans , by Region USD Million (2015-2020)
  • Table 3. Nephro Genetic Testing MRIs , by Region USD Million (2015-2020)
  • Table 4. Nephro Genetic Testing Ultrasounds , by Region USD Million (2015-2020)
  • Table 5. Nephro Genetic Testing Kidney Function Test , by Region USD Million (2015-2020)
  • Table 6. Nephro Genetic Testing Urinalysis , by Region USD Million (2015-2020)
  • Table 7. South America Nephro Genetic Testing, by Country USD Million (2015-2020)
  • Table 8. South America Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 9. South America Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 10. South America Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 11. Brazil Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 12. Brazil Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 13. Brazil Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 14. Argentina Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 15. Argentina Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 16. Argentina Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 17. Rest of South America Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 18. Rest of South America Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 19. Rest of South America Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 20. Asia Pacific Nephro Genetic Testing, by Country USD Million (2015-2020)
  • Table 21. Asia Pacific Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 22. Asia Pacific Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 23. Asia Pacific Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 24. China Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 25. China Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 26. China Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 27. Japan Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 28. Japan Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 29. Japan Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 30. India Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 31. India Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 32. India Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 33. South Korea Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 34. South Korea Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 35. South Korea Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 36. Taiwan Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 37. Taiwan Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 38. Taiwan Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 39. Australia Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 40. Australia Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 41. Australia Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 42. Rest of Asia-Pacific Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 43. Rest of Asia-Pacific Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 44. Rest of Asia-Pacific Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 45. Europe Nephro Genetic Testing, by Country USD Million (2015-2020)
  • Table 46. Europe Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 47. Europe Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 48. Europe Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 49. Germany Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 50. Germany Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 51. Germany Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 52. France Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 53. France Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 54. France Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 55. Italy Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 56. Italy Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 57. Italy Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 58. United Kingdom Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 59. United Kingdom Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 60. United Kingdom Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 61. Netherlands Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 62. Netherlands Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 63. Netherlands Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 64. Rest of Europe Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 65. Rest of Europe Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 66. Rest of Europe Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 67. MEA Nephro Genetic Testing, by Country USD Million (2015-2020)
  • Table 68. MEA Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 69. MEA Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 70. MEA Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 71. Middle East Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 72. Middle East Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 73. Middle East Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 74. Africa Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 75. Africa Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 76. Africa Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 77. North America Nephro Genetic Testing, by Country USD Million (2015-2020)
  • Table 78. North America Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 79. North America Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 80. North America Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 81. United States Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 82. United States Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 83. United States Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 84. Canada Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 85. Canada Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 86. Canada Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 87. Mexico Nephro Genetic Testing, by Test USD Million (2015-2020)
  • Table 88. Mexico Nephro Genetic Testing, by End-Use Industries USD Million (2015-2020)
  • Table 89. Mexico Nephro Genetic Testing, by Diagnosis USD Million (2015-2020)
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Nephro Genetic Testing: by Diagnosis(USD Million)
  • Table 96. Nephro Genetic Testing CT Scans , by Region USD Million (2021-2026)
  • Table 97. Nephro Genetic Testing MRIs , by Region USD Million (2021-2026)
  • Table 98. Nephro Genetic Testing Ultrasounds , by Region USD Million (2021-2026)
  • Table 99. Nephro Genetic Testing Kidney Function Test , by Region USD Million (2021-2026)
  • Table 100. Nephro Genetic Testing Urinalysis , by Region USD Million (2021-2026)
  • Table 101. South America Nephro Genetic Testing, by Country USD Million (2021-2026)
  • Table 102. South America Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 103. South America Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 104. South America Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 105. Brazil Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 106. Brazil Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 107. Brazil Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 108. Argentina Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 109. Argentina Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 110. Argentina Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 111. Rest of South America Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 112. Rest of South America Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 113. Rest of South America Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 114. Asia Pacific Nephro Genetic Testing, by Country USD Million (2021-2026)
  • Table 115. Asia Pacific Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 116. Asia Pacific Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 117. Asia Pacific Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 118. China Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 119. China Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 120. China Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 121. Japan Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 122. Japan Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 123. Japan Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 124. India Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 125. India Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 126. India Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 127. South Korea Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 128. South Korea Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 129. South Korea Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 130. Taiwan Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 131. Taiwan Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 132. Taiwan Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 133. Australia Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 134. Australia Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 135. Australia Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 136. Rest of Asia-Pacific Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 137. Rest of Asia-Pacific Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 138. Rest of Asia-Pacific Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 139. Europe Nephro Genetic Testing, by Country USD Million (2021-2026)
  • Table 140. Europe Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 141. Europe Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 142. Europe Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 143. Germany Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 144. Germany Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 145. Germany Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 146. France Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 147. France Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 148. France Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 149. Italy Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 150. Italy Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 151. Italy Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 152. United Kingdom Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 153. United Kingdom Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 154. United Kingdom Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 155. Netherlands Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 156. Netherlands Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 157. Netherlands Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 158. Rest of Europe Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 159. Rest of Europe Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 160. Rest of Europe Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 161. MEA Nephro Genetic Testing, by Country USD Million (2021-2026)
  • Table 162. MEA Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 163. MEA Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 164. MEA Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 165. Middle East Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 166. Middle East Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 167. Middle East Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 168. Africa Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 169. Africa Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 170. Africa Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 171. North America Nephro Genetic Testing, by Country USD Million (2021-2026)
  • Table 172. North America Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 173. North America Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 174. North America Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 175. United States Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 176. United States Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 177. United States Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 178. Canada Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 179. Canada Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 180. Canada Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 181. Mexico Nephro Genetic Testing, by Test USD Million (2021-2026)
  • Table 182. Mexico Nephro Genetic Testing, by End-Use Industries USD Million (2021-2026)
  • Table 183. Mexico Nephro Genetic Testing, by Diagnosis USD Million (2021-2026)
  • Table 184. Research Programs/Design for This Report
  • Table 185. Key Data Information from Secondary Sources
  • Table 186. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nephro Genetic Testing: by Diagnosis USD Million (2015-2020)
  • Figure 5. South America Nephro Genetic Testing Share (%), by Country
  • Figure 6. Asia Pacific Nephro Genetic Testing Share (%), by Country
  • Figure 7. Europe Nephro Genetic Testing Share (%), by Country
  • Figure 8. MEA Nephro Genetic Testing Share (%), by Country
  • Figure 9. North America Nephro Genetic Testing Share (%), by Country
  • Figure 10. Global Nephro Genetic Testing share by Players 2020 (%)
  • Figure 11. BCG Matrix for key Companies
  • Figure 12. Centogene (Germany) Revenue, Net Income and Gross profit
  • Figure 13. Centogene (Germany) Revenue: by Geography 2020
  • Figure 14. MeGenome (India) Revenue, Net Income and Gross profit
  • Figure 15. MeGenome (India) Revenue: by Geography 2020
  • Figure 16. Blueprint Genetics Oy (Finland) Revenue, Net Income and Gross profit
  • Figure 17. Blueprint Genetics Oy (Finland) Revenue: by Geography 2020
  • Figure 18. Invitae Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Invitae Corporation (United States) Revenue: by Geography 2020
  • Figure 20. Natera Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Natera Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Global Nephro Genetic Testing: by Diagnosis USD Million (2021-2026)
  • Figure 23. South America Nephro Genetic Testing Share (%), by Country
  • Figure 24. Asia Pacific Nephro Genetic Testing Share (%), by Country
  • Figure 25. Europe Nephro Genetic Testing Share (%), by Country
  • Figure 26. MEA Nephro Genetic Testing Share (%), by Country
  • Figure 27. North America Nephro Genetic Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Centogene (Germany)
  • MeGenome (India)
  • Blueprint Genetics Oy (Finland)
  • Invitae Corporation (United States)
  • Natera Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation